In the last week, the United States market has stayed flat, yet over the past 12 months, it has risen by an impressive 30%, with earnings anticipated to grow by 16% annually in the coming years. In this dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and potential for significant revenue expansion in alignment with these positive market trends.

Top 10 High Growth Tech Companies In The United States

Name	Revenue Growth	Earnings Growth	Growth Rating
Marker Therapeutics	61.33%	65.71%	★★★★★★
Palantir Technologies	27.35%	30.93%	★★★★★★
Reddit	22.05%	27.75%	★★★★★★
Fabrinet	20.36%	22.11%	★★★★★★
Sandisk	34.05%	49.66%	★★★★★★
Gorilla Technology Group	54.35%	95.02%	★★★★★☆
Zscaler	15.95%	49.84%	★★★★★☆
Circle Internet Group	20.25%	46.50%	★★★★★☆
Duos Technologies Group	36.60%	141.19%	★★★★★☆
KVH Industries	25.44%	135.75%	★★★★★☆

Below we spotlight a couple of our favorites from our exclusive screener.

Clearfield (CLFD)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Clearfield, Inc. designs, manufactures, and distributes fiber management, protection, and delivery products both in the United States and internationally with a market cap of approximately $417.76 million.

Operations: The company generates revenue primarily from its Clearfield segment, amounting to $154.78 million. It focuses on designing, manufacturing, and distributing fiber management products in both domestic and international markets.

Clearfield's recent performance underscores its role in the high-growth tech sector, evidenced by a 15.3% annual revenue growth and an impressive 61.1% surge in earnings per year, outpacing the broader US market significantly. Despite a challenging fiscal quarter with a net loss of $0.614 million, strategic R&D investments have positioned it well for future technology advancements in communications infrastructure—a sector becoming increasingly vital as digital connectivity demands soar. The company's active participation in numerous industry conferences, such as Data Center World and Adtran Summit, highlights its commitment to maintaining a strong presence and influence within the tech community. These efforts are complemented by a robust share repurchase program where Clearfield has bought back 17.04% of its shares for $61.71 million since 2014, signaling confidence in its financial health and long-term prospects.

Agilysys (AGYS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Agilysys, Inc. is a company that develops and markets software-enabled solutions and services for the hospitality industry across North America, Europe, the Asia-Pacific, and India, with a market cap of $1.87 billion.

Operations: The company generates revenue primarily through providing software solutions to the global hospitality industry, amounting to $310.64 million.

Agilysys, a key player in the hospitality technology sector, is demonstrating robust growth with a 13.7% increase in annual revenue and an even more impressive 27.3% rise in earnings per year. This performance is bolstered by strategic R&D investments amounting to $5.4 million last year, representing about 8.6% of their total revenue, facilitating continuous innovation in integrated commerce solutions for lodging and food service industries. Recent expansions include enhanced partnerships with FreedomPay and new deployments at high-profile resorts like Deep Blue Hotel & Hot Springs, emphasizing Agilysys's commitment to providing comprehensive, scalable solutions that enhance guest experiences while driving operational efficiency. These developments not only strengthen its market position but also align well with evolving industry demands for more integrated and guest-centric technology solutions.

Kiniksa Pharmaceuticals International (KNSA)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on developing and commercializing medical therapies across the United States, the United Kingdom, and internationally, with a market cap of approximately $3.29 billion.

Operations: Kiniksa Pharmaceuticals generates revenue primarily through developing and delivering therapeutic medicines, with reported earnings of $677.56 million.

Kiniksa Pharmaceuticals International has pivoted impressively from a net loss to substantial profitability within a year, showcasing a dynamic shift in its financial health. In 2025, the company reported an increase in annual revenue to $677.56 million from $423.24 million the previous year, marking a growth of 60%. This surge is mirrored in its net income, which swung from a loss of $43.19 million to a profit of $59.01 million. These gains are underscored by significant R&D investments aimed at fostering innovation and securing competitive advantage in the biotech sector. At the recent TD Cowen Health Care Conference, Kiniksa highlighted strategies that could further enhance their market position, emphasizing their commitment to leveraging scientific research for better therapeutic outcomes.

Key Takeaways

• Explore the 67 names from our US High Growth Tech and AI Stocks screener here.
• Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.